Lab-grown pancreatic organoids to understand type 1 diabetes and treatment responses
Advanced pancreatic-immune organoid models of type 1 diabetes subtypes and therapeutic responses
Using patient-derived pancreatic organoids to see why some people with type 1 diabetes respond differently to immune therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11250094 on NIH RePORTER |
What this research studies
Researchers will turn patient cells into induced pluripotent stem cells and grow them into mini pancreatic organoids using automated, high-throughput lab systems. They will compare organoids made from people who progressed differently to type 1 diabetes or who did and did not respond to immune treatments like teplizumab. The team will expose these organoids to immune cells and immune-targeting drugs to look for intrinsic beta cell features linked to progression and treatment response. Findings aim to reveal why therapies work for some patients and not others.
Who could benefit from this research
Good fit: Ideal candidates include people with or at risk for type 1 diabetes who can provide blood or tissue samples or who participated in related clinical trials.
Not a fit: People with long-standing type 1 diabetes who have minimal remaining beta cell function or those unable to provide samples may not get direct benefit.
Why it matters
Potential benefit: Could help predict who will benefit from immune therapies and guide treatments that better preserve insulin-producing beta cells.
How similar studies have performed: Immune drugs like teplizumab have shown the ability to delay clinical diabetes, and organoid/iPSC models have been developed before, but applying high-throughput organoid systems to predict individual treatment response is relatively new.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Herold, Kevan C — Yale University
- Study coordinator: Herold, Kevan C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.